Top Analyst Upgrades and Downgrades: Biogen, Broadcom, Devon Energy, Gilead, Mondelez, Urban Outfitters and More

Print Email

comScore Inc. (NASDAQ: SCOR) was downgraded to Neutral from Buy with a $34 price target (versus a $31.81 close) at SunTrust Robinson Humphrey.

Crown Castle International Corp. (NYSE: CCI) was raised to Outperform from Perform with a $109 price target at Oppenheimer.

Equinix Inc. (NASDAQ: EQIX) was raised to Outperform from Perform with a $420 price target at Oppenheimer.

Five Below Inc. (NASDAQ: FIVE) was started as Neutral with a $42 price target (versus a $43.40 close) at Goldman Sachs.

Greif Inc. (NYSE: GEF) was raised to Buy from Neutral at Merrill Lynch.

Medpace Holdings Inc. (NASDAQ: MEDP) was started as Hold with a $32.50 price target (versus a $30.70 close) at Jefferies. Credit Suisse started coverage as Outperform with a $35 target price.

Michaels Companies Inc. (NYSE: MIK) was raised to Outperform from Neutral at Credit Suisse, but the firm reaffirmed its $29 price target.

Mylan Inc. (NASDAQ: MYL) was maintained as a Sector Perform rating and the price target was cut to $48 from $52 at RBC Capital Markets.

Oclaro Inc. (NASDAQ: OCLR) was reiterated as Buy and the price target was raised to $10.00 from $7.50 (versus an $8.39 close) at Stifel.

ONEOK Partners L.P. (NYSE: OKS) was raised to Neutral from Underweight with a $40 price target (versus a $39.29 close) at JPMorgan.

Seagate Technology PLC (NASDAQ: STX) was reiterated as Buy and the price target was raised to $38 from $32 (versus a $33.92 close) at Jefferies.

Verifone Systems Inc. (NYSE: PAY) was downgraded to Hold from Buy at Argus after last week’s weak earnings and outlook crushed its shares.

Other key analyst calls from Tuesday were as follows:

Ellie Mae Inc. (NYSES: ELLI) was started as Overweight with a $124 price target (versus a $98.80 close) at Pacific Crest.

Protagonist Therapeutics Inc. (NASDAQ: PTGX) was started as Overweight with a price target of $18 at Barclays. Leerink assigned a Outperform rating and $17 price target, and BMO Capital Markets started coverage with a Outperform rating and $21 price target. Shares closed at $12.08.

Is Cepheid a deal that has more sizzle for Danaher than meets the eye?

Also see the energy stocks that analysts want you to buy now.

Five speculative biotech analyst picks under $10 for massive upside.

Friday’s top analyst upgrades and downgrades included Carnival, Ciena, MercadoLibre, Spark Therapeutics, Smith & Wesson, Teva Pharmaceutical, Verifone and close to a dozen more.